297 related articles for article (PubMed ID: 30607677)
1. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
5. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
6. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
7. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
9. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
10. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
12. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
13. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
15. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part).
Kikuchi K; Yamazaki N; Nozawa K; Fukuda H; Shibata T; Machida R; Hamaguchi T; Takashima A; Shoji H; Boku N; Takatsuka S; Takenouchi T; Nishina T; Yoshikawa S; Takahashi M; Hasegawa A; Kawazoe A; Masuishi T; Mizutani H; Kiyohara Y
Support Care Cancer; 2022 May; 30(5):4497-4504. PubMed ID: 35113224
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
17. Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Gürbüz M; Akkuş E; Utkan G
J Oncol Pharm Pract; 2021 Mar; 27(2):480-484. PubMed ID: 32623964
[TBL] [Abstract][Full Text] [Related]
18. Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Beech J; Germetaki T; Judge M; Paton N; Collins J; Garbutt A; Braun M; Fenwick J; Saunders MP
Future Oncol; 2018 Oct; 14(24):2531-2541. PubMed ID: 29727211
[TBL] [Abstract][Full Text] [Related]
19. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]